DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients with primary open-angle glaucoma or ocular ...
Combination therapy seeks to improve intraocular pressure lowering by pairing a novel EVP-targeting agent with prostaglandin analogue standard of care DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results